Table 3 Characteristics for four study subjects that had a time to progression of two years or longer
| Â | Case number | |||
|---|---|---|---|---|
| Â | 1 | 13 | 6 | 2 |
BRCA1 mutation | C61G | C61G | 5382insC | 5382insC |
Age at treatment | 56 | 34 | 48 | 66 |
Estrogen receptor | Negative | Negative | Positive | Negative |
Progesterone receptor | Positive | Negative | Positive | Negative |
HER2 status | Negative | Negative | Negative | Negative |
Site of metastases | Lung | Lung, liver | Liver | Liver |
Number of sites of metastases | 1 | 2 | 1 | 1 |
Prior adjuvant chemotherapy | Yes | Yes | Yes | Yes |
Line of therapy of metastatic disease | 1 | 3 | 1 | 2 |
Response | Complete | Complete | Partial | Partial |
Time from treatment to progression (months) | 36 | 27 | 27 | 28 |